Thomas J L, Berko E A, Faustino A, Myers R P, Strickler R C
Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO 63110.
J Steroid Biochem. 1988 Nov;31(5):785-93. doi: 10.1016/0022-4731(88)90287-7.
In human pregnancy, placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase produce progesterone from pregnenolone and metabolize fetal dehydroepiandrosterone sulfate to androstenedione, an estrogen precursor. The enzyme complex was solubilized from human placental microsomes using the anionic detergent, sodium cholate. Purification (500-fold, 3.9% yield) was achieved by ion exchange chromatography (Fractogel-TSK DEAE 650-S) followed by hydroxylapatite chromatography (Bio-Gel HT). The purified enzyme was detected as a single protein band in sodium dodecylsulfate-polyacrylamide gel electrophoresis (monomeric Mr = 19,000). Fractionation by gel filtration chromatography at constant specific enzyme activity supported enzyme homogeneity and determined the molecular mass (Mr = 76,000). The dehydrogenase and isomerase activities copurified. Kinetic constants were determined at pH 7.4, 37 degrees C for the oxidation of pregnenolone (Km = 1.9 microM, Vmax = 32.6 nmol/min/mg) and dehydroepiandrosterone (Km = 2.8 microM, Vmax = 32.0 nmol/min/mg) and for the isomerization of 5-pregnene-3,20-dione (Km = 9.7 microM, Vmax = 618.3 nmol/min/mg) and 5-androstene-3,17-dione (Km = 23.7 microM, Vmax = 625.7 nmol/min/mg). Mixed substrate analyses showed that the dehydrogenase and isomerase reactions use the appropriate pregnene and androstene steroids as alternative, competitive substrates. Dixon analyses demonstrated competitive inhibition of the oxidation of pregnenolone and dehydroepiandrosterone by both product steroids, progesterone and androstenedione. The enzyme has a 3-fold higher affinity for androstenedione than for progesterone as an inhibitor of dehydrogenase activity. Based on these competitive patterns of substrate utilization and product inhibition, the pregnene and androstene activities of 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase may be expressed at a single catalytic site on one protein in human placenta.
在人类妊娠过程中,胎盘3β-羟基-5-烯-类固醇脱氢酶和类固醇5→4-烯异构酶可将孕烯醇酮转化为孕酮,并将胎儿硫酸脱氢表雄酮代谢为雄烯二酮(一种雌激素前体)。使用阴离子去污剂胆酸钠从人胎盘微粒体中溶解该酶复合物。通过离子交换色谱法(Fractogel-TSK DEAE 650-S),然后是羟基磷灰石色谱法(Bio-Gel HT)进行纯化(纯化500倍,产率3.9%)。纯化后的酶在十二烷基硫酸钠-聚丙烯酰胺凝胶电泳中检测为单一蛋白条带(单体Mr = 19,000)。在恒定的比酶活性下通过凝胶过滤色谱法分级分离支持酶的同质性并确定了分子量(Mr = 76,000)。脱氢酶和异构酶活性共纯化。在pH 7.4、37℃下测定了孕烯醇酮氧化(Km = 1.9μM,Vmax = 32.6 nmol/min/mg)、脱氢表雄酮氧化(Km = 2.8μM,Vmax = 32.0 nmol/min/mg)以及5-孕烯-3,20-二酮异构化(Km = 9.7μM,Vmax = 618.3 nmol/min/mg)和5-雄烯-3,17-二酮异构化(Km = 23.7μM,Vmax = 625.7 nmol/min/mg)的动力学常数。混合底物分析表明,脱氢酶和异构酶反应使用适当的孕烯和雄烯类固醇作为替代的竞争性底物。狄克逊分析表明,产物类固醇孕酮和雄烯二酮对孕烯醇酮和脱氢表雄酮的氧化具有竞争性抑制作用。作为脱氢酶活性的抑制剂,该酶对雄烯二酮的亲和力比对孕酮高3倍。基于这些底物利用和产物抑制的竞争模式,人胎盘中3β-羟基-5-烯-类固醇脱氢酶和类固醇5→4-烯异构酶的孕烯和雄烯活性可能在一种蛋白质的单个催化位点上表达。